1. Home
  2. Interim Alert Glucosamine Holding Statement and Talking Points

Interim Alert: Glucosamine Standby Statement and Talking Points

JUNE 2026

The following information is provided exclusively as a CRN member benefit and should not be distributed outside your organization.

Re: Hawkinson et al. (2026). "Hyperglycosylation is a metabolic driver of Alzheimer's disease."
Nature Metabolism | Published June 9, 2026 | DOI: 10.1038/s42255-026-01538-4


CRN Standby Statement

CRN supports continued research into how nutrition, metabolism, and healthy aging intersect. The new study from the University of Florida (UF) raises an interesting mechanistic hypothesis involving glycan metabolism, but the human data are observational and should not be misinterpreted or misreported as proof that glucosamine causes Alzheimer's disease progression. Notably, this study does not impact the safety profile for glucosamine supplementation when used as directed for joint support in generally healthy adults.

Glucosamine is commonly used by people with joint pain and osteoarthritis. These conditions may be associated with reduced mobility, lower physical activity, and frailty — factors that are themselves linked to dementia outcomes, and that do not appear to have been fully accounted for, making this a key limitation of the study.


These findings should also be considered as part of the overall body of evidence. Previous analyses in nearly 500,000 participants with follow-up of 9 to 12 years have found no significant association with incident Alzheimer's disease or have reported lower dementia risk among glucosamine users. Taken together, the evidence is mixed and hypothesis-generating, not definitive.

Consumers with mild cognitive impairment (MCI), Alzheimer’s disease, or complex medical conditions should review all their supplements, including glucosamine, with a qualified healthcare provider rather than making abrupt changes based on a single study or media headline. In general, anyone considering starting, stopping, or changing a glucosamine regimen—especially older adults or those on multiple medications—should consult their healthcare professional to determine what is appropriate for their overall health.

Talking Points

1. Association Is Not Causation

  • The human data presented in the paper are a retrospective electronic health record (EHR) analysis from a single academic health system. EHR analyses generate hypotheses; they cannot establish that glucosamine independently causes faster Alzheimer's progression. [1]
  • In the UF Health public statement about the study, co-author Matt Gentry, Ph.D., stated: “...it’s an association and not proof of causality...”
  • While the proposed mechanism of action is biologically plausible and hypothesis-generating, additional research, including a randomized clinical trial, would be needed to establish causation.
     

2.  Confounding Variables Were Not Accounted For

  • Glucosamine is commonly taken by older adults with joint pain, osteoarthritis, and reduced mobility. These conditions are independently associated with frailty, lower physical activity, higher healthcare utilization, and elevated dementia and mortality risk -- all factors that could explain the observed association without any direct effect of the supplement. [2,3,4]
  • The EHR analysis does not appear to have adjusted for osteoarthritis diagnosis, joint pain severity, physical activity level, functional mobility, frailty index, BMI, depression, opioid use, or falls -- all variables that may systematically differ between glucosamine users and non-users and are independently linked to cognitive and mortality outcomes. [1]
     

3.  Physical Inactivity Is an Established, Uncontrolled Dementia Risk Factor

  • Physical inactivity is one of 12 modifiable dementia risk factors identified by the 2020 Lancet Commission on Dementia Prevention, Intervention, and Care. Addressing all 12 modifiable risk factors could potentially prevent or delay up to 40% of dementia cases worldwide. [5]
  • Recent research, including a meta-analysis and observational study, showed that physical activity is associated with a significant reduction in all-cause dementia and Alzheimer’s disease, and slower cognitive and functional decline in those with elevated amyloid burden, respectively. [6,7]
  • Because glucosamine users may have more joint disease and reduced mobility than non-users, they are likely less physically active -- introducing a systematic bias that the EHR matching did not address and that could plausibly explain the observed 25% progression risk increase. [2,5,6]
     

4.  Other Large-Scale Studies Show No Harm Signal — and Suggest Potential Benefit

  • The UF findings are inconsistent with multiple large-scale longitudinal UK Biobank analyses in cognitively healthy populations, showing that glucosamine use was either not associated with incident dementia or Alzheimer’s disease, or was associated with a lower risk of these diseases. [2,3,4,8]
  • Importantly, the UF study's own authors acknowledge this prior literature, stating that glucosamine appears safe and potentially protective for a healthy brain and that their findings do not contradict earlier studies but qualify them to the MCI/ADRD population. [1]


References

  1. Hawkinson TR, Liu Z, Ribas RA, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. Published June 9, 2026. DOI: 10.1038/s42255-026-01538-4

  2. Ai B, Chen L, Cai M, et al. No associations between glucosamine supplementation and dementia or Parkinson's disease: findings from a large prospective cohort study. Journals of Gerontology: Series A. 2024;79(2):glad123.  DOI: 10.1093/gerona/glad123

  3. Zhou C, Zhang Y, Yang S, et al. Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population. Alzheimer's Research & Therapy. 2023;15:152. . DOI: 10.1186/s13195-023-01295-6

  4. Zheng J, Ni C, Zhang Y, et al. Association of regular glucosamine use with incident dementia: evidence from a longitudinal cohort and Mendelian randomization study. BMC Medicine. 2023;21:114. DOI: 10.1186/s12916-023-02816-8

  5. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-446. DOI: 10.1016/S0140-6736(20)30367-6

  6. Iso-Markku P, et al. Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. BMJ Open. 2022;12. https://bjsm.bmj.com/content/56/12/701

  7. Lussier FZ, et al. Physical activity as a modifiable risk factor in preclinical Alzheimer's disease. Nature Medicine. 2025. DOI: 10.1038/s41591-025-03955-6

  8. Xu C, Hou Y, Fang X, et al.. The role of type 2 diabetes in the association between habitual glucosamine use and dementia: a prospective cohort study. Alzheimer's Research & Therapy. 2022;14:196. DOI: 10.1186/s13195-022-01137-x